20-F: NewGenIVF Shifts to High-Risk Diversification Amid Core Business Decline

NewGenIVF Group Limited reported a net income driven by non-cash gains in 2025, despite a significant decline in its core fertility services revenue and a widening operating loss, as it aggressively diversifies into digital assets and real estate.

Summary

• Revenue decreased by 13.01% from US$5,433,375 in 2024 to US$4,726,433 in 2025, primarily due to a 28.11% drop in IVF treatment service revenue.
• Gross profit declined by 47.68% from US$1,826,894 in 2024 to US$955,846 in 2025, with gross margin falling from 33.6% to 20.2%.
• Operating expenses surged by 291.05% to US$11,682,307 in 2025, leading to a wider operating loss of US$(10,726,461) compared to US$(1,160,495) in 2024.
• Net income of US$9,728,723 in 2025 was primarily driven by a non-cash bargain purchase gain of US$21,653,835 from the acquisition of MicroSort and Nodexus businesses.
• The company is undergoing a rapid business transformation, expanding from fertility services into real estate development, digital asset management, and mining.
• NewGenIVF plans to invest up to US$30 million in staking Solana (SOL) tokens, currently holding 10,000.23 SOL tokens with an unrealized loss of approximately US$1.397 million.
• A joint venture for real estate development in Ras Al Khaimah, UAE, projects a net return of up to US$67 million, but a definitive Sales and Purchase Agreement is not yet executed.
• The company acquired MicroSort sperm-sorting technology and Nodexus advanced cytometry intellectual property, resulting in significant bargain purchase gains.
• A material weakness in internal control over financial reporting was identified due to a lack of adequately skilled staff with U.S. GAAP knowledge.
• CEO Wing Fung Alfred Siu was served a summons in Hong Kong for alleged violations related to commercial surrogacy arrangements, though the company states it does not advertise such services in Hong Kong.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with significant concern. While a non-cash bargain purchase gain led to reported net income, the core business is deteriorating, and the aggressive, high-risk diversification into unrelated sectors with acknowledged management inexperience and regulatory uncertainty creates substantial downside risk.

Positives

• Reported a net income of US$9,728,723 in 2025, a significant improvement from a net loss of US$(474,101) in 2024, primarily due to non-cash bargain purchase gains.
• Achieved a bargain purchase gain of US$21,653,835 in 2025 from the acquisitions of MicroSort and Nodexus businesses, enhancing technological capabilities.
• Successfully transferred its listing to the Nasdaq Capital Market and regained compliance with Nasdaq's minimum bid price rule and other listing requirements in early 2025.
• Introduced fertility referral services in Kyrgyzstan, generating US$820,570 in new revenue in 2025.
• Maintains access to an equity line of credit facility of up to US$100,000,000 from White Lion Capital, with US$15.55 million drawn to date, providing capital flexibility.
• The acquisition of MicroSort technology provides exclusive rights for pre-conception gender selection and prevention of gender-related hereditary diseases, with a valuation of US$3,495,335.
• The acquisition of Nodexus advanced cytometry intellectual property, valued at US$17.9 million, is central to a pivot towards a high-margin, technology-licensing business model.
• The company has established a second clinic in Thailand to mitigate operational risks and potential interruptions at its primary facility.

Negatives

• Total revenue decreased by 13.01% from US$5,433,375 in 2024 to US$4,726,433 in 2025, indicating a decline in core business performance.
• IVF treatment service revenue, the primary source, decreased by 28.11% from US$5,433,375 in 2024 to US$3,905,863 in 2025, attributed to management changes and new clinic setup.
• Gross profit decreased significantly by 47.68% to US$955,846 in 2025, and gross margin dropped from 33.6% to 20.2%, reflecting increased unit service costs and decreased marketing efficiency.
• Operating expenses increased by 291.05% to US$11,682,307 in 2025, primarily due to professional fees for new ventures, increased staff salaries, and write-offs.
• Operating loss widened substantially from US$(1,160,495) in 2024 to US$(10,726,461) in 2025, indicating a deterioration in underlying operational profitability.
• The company holds 10,000.23 SOL tokens with an unrealized loss of approximately US$1.397 million as of the filing date, and has not yet begun staking to earn rewards.
• A material weakness in internal control over financial reporting was identified due to a lack of adequately skilled staff with U.S. GAAP knowledge.
• CEO Wing Fung Alfred Siu was served a summons for alleged violations of Hong Kong's Human Reproductive Technology Ordinance related to commercial surrogacy arrangements, which could lead to reputational harm and potential penalties.
• The company's real estate development project in the UAE is currently based on a reservation deposit, with no definitive Sales and Purchase Agreement executed, introducing uncertainty over projected revenues.

Risks

• Inability to continue operating as a going concern due to insufficient capital to bridge potential financial and liquidity shortfalls, with US$5,266,000 in convertible promissory notes outstanding as of March 30, 2026.
• Significant dilution to shareholders from potential issuance of additional Ordinary Shares through equity lines of credit, warrants, convertible notes, and the Share Incentive Plan.
• Intense competition in the fertility market from more established players with greater resources and brand recognition.
• Limited operating history with its current platform of solutions and new diversified ventures, making future financial performance difficult to predict.
• Substantial risks associated with the rapid business transformation into real estate development, digital asset management, and mining, including inability to manage diverse business lines and lack of management experience in these new sectors.
• High price volatility of SOL tokens, staking and liquidity risks (unbonding periods), operational and validator risks, custodial and security risks (OSL insurance limits), and regulatory uncertainty in the digital asset sector.
• Unique and substantial risks related to the Solana network's technology, governance, and ecosystem, including network performance and outages, reliance on third-party software, technological obsolescence, and uncertain tokenomics.
• Exposure to novel, evolving, and highly uncertain regulatory and operational landscapes for tokenization advisory services, including potential classification of tokenized assets as securities and the need for regulatory approvals.
• Numerous risks associated with real estate development projects, including vulnerability to regional economic conditions, regulatory changes, market fluctuations in the UAE, construction delays, cost overruns, and reliance on third-party partners.
• The recent escalation of the Iran-Israel-US conflict poses significant economic and political risks, potentially disrupting oil supplies, impacting the UAE real estate sector, and causing a broad economic downturn across Asia.
• Valuation of acquired intellectual property (MicroSort, Nodexus) is complex and subjective, and the actual commercial value may not be realized, potentially leading to impairment charges.
• Dependence on positive client references for marketing, with the loss or dissatisfaction of any client potentially harming brand and reputation.
• Risk of delisting from Nasdaq if the company fails to meet listing requirements in the future, despite recent compliance efforts.
• Failure to attract new clients or maintain existing client demographics in the competitive fertility market.
• Exposure to potential liabilities inherent in providing medical services, with no current insurance coverage for operations or professional malpractice liability.
• Reliance on third-party suppliers for pharmaceuticals, medical equipment, and consumables, with risks of defective or counterfeit products.
• Risks from related party transactions, which may present conflicts of interest and not always align with the company's or other shareholders' best interests.
• Compliance challenges in a highly regulated industry, including licensing, patient rights protection, privacy and security requirements, fraud and abuse laws, and advertisement laws across multiple jurisdictions.
• Legal and regulatory risks related to advertising or offering gender selection services in certain jurisdictions, such as Hong Kong's HRTO, which prohibits gender selection for non-medical purposes and commercial surrogacy arrangements.
• Potential adverse effects from significant tariffs or other import restrictions imposed by the U.S. and related countermeasures by impacted countries.
• Litigation risks, including regulatory actions, disputes, and claims, which could be costly, time-consuming, and damage reputation.
• Challenges in identifying, integrating, and managing acquisitions, strategic investments, partnerships, or alliances, potentially leading to diversion of management attention, business disruption, and dilution.
• Changes in effective tax rate or tax liability due to various factors, including changes in tax laws, treaties, and interpretations.
• Adverse effects on reported financial results from changes in U.S. GAAP accounting principles, requiring costly system changes and potential reporting fluctuations.
• Non-compliance with anti-corruption, anti-bribery, and anti-money laundering laws, which could lead to criminal or civil liability and reputational harm.
• Inflation risk, particularly from rising oil prices due to geopolitical conflicts, which could increase operational costs that may not be passed on to customers.

Future Outlook

NewGenIVF aims to provide tailored ARS solutions and expand its market share in Asia Pacific through strategic acquisitions, partnerships, and continuous investment in laboratories and facilities. The company intends to offer broad fertility services for fertility tourists, enhance customer experience with integrated hospitality arrangements, and develop advanced facilities for ARS research. It also plans to increase brand awareness through social media and business development, and introduce innovative treatment services like IVF mental health support. The company's long-term objective is to build a comprehensive, sophisticated, and high-end ARS platform, but this is subject to significant risks and uncertainties related to its rapid diversification into new, unrelated business lines.

Management Comments

• "The Company is always closely monitoring the market for opportunities and has also been carrying out various fundraising projects to improve the Company’s cash flow position."
• "NewGenIvf believes that one of its key competitive advantages is its ability to provide a broad range of services, and NewGenIvf does not believe any competitors have developed a similar broad range services in Asia Pacific at this time."
• "NewGenIvf believes that maintaining and enhancing its brand is important to support the marketing and sale of its existing and future solutions to new clients and expand sales of its solutions to existing clients."
• "NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs."
• "NewGenIvf expects its cost structure to evolve as it develops and expands its business. As NewGenIvf continues to develop new services and technologies, NewGenIvf expects to incur additional costs in relation to its raw materials procurement, production and sales and marketing, among other things."
• "Management is committed to improving the internal controls over financial reporting and will undertake consistent improvements or enhancements on an ongoing basis."
• "The Company’s executive officers oversee the strategic processes to safeguard data and comply with relevant regulations and has overall responsibility for evaluating cybersecurity risks, as well as related policies and risks in connection with the company’s supply chain, suppliers and other service providers."

Industry Context

StockSavvy.ai notes that NewGenIVF's pivot from a specialized fertility services provider to a highly diversified conglomerate with interests in digital assets, real estate, and mining is a significant departure from typical industry trends. While diversification can mitigate risks, this aggressive and rapid expansion into unrelated, high-risk sectors, particularly digital assets and real estate in volatile regions, contrasts with the more focused growth strategies seen in the mature healthcare and biotech industries. The fertility market itself is growing, driven by demographic shifts and technological advancements, but NewGenIVF's declining core revenue suggests it is not fully capitalizing on this trend. The company's strategy to leverage technology licensing (MicroSort, Nodexus) is more aligned with biotech industry trends, but its execution across such a broad portfolio of ventures is highly unusual and introduces substantial operational and management challenges.

Comparison to Industry Standards

• NewGenIVF's gross margin of 20.2% in 2025 is significantly lower than typical gross margins for specialized healthcare providers, which often range from 40-60% or higher, indicating a less efficient core operation or aggressive pricing strategies.
• The company's rapid diversification into unrelated sectors like digital asset staking and real estate development is highly atypical for a publicly traded fertility services company, making direct comparisons to industry standards difficult and highlighting a unique, high-risk strategic direction.
• The reported unrealized loss of US$1.397 million on Solana (SOL) tokens, despite a planned US$30 million investment, underscores the extreme volatility and speculative nature of its digital asset strategy, which is not a standard practice for healthcare companies.
• The identification of a material weakness in internal control over financial reporting due to a lack of U.S. GAAP expertise is a significant governance concern, contrasting with the robust financial reporting standards expected of publicly traded companies, especially those listed on Nasdaq.
• The average cost per IVF cycle by NewGenIVF is around US$7,000 (excluding medication), which is presented as 'relatively low cost' compared to the US market, suggesting a competitive pricing strategy in Asia-Pacific, but without specific comparable company data, it's hard to benchmark effectively.

Management Changes

Corporate Governance

Legal Proceedings

• Wing Fung Alfred Siu and Hei Yue Tina Fong were arrested on April 25, 2025, in Hong Kong for allegedly violating sections of the Human Reproductive Technology Ordinance (HRTO) related to sex selection, advertising sex selection services, commercial surrogacy arrangements, and advertising surrogacy arrangements. They were released on bail of HKD 3,000 (US$390). The statutory limitation period for these specific alleged offenses has lapsed.
• Wing Fung Alfred Siu was served a summons on October 26, 2025, for allegedly violating section 17(2) of the HRTO, which prohibits commercial surrogacy arrangements and advertising surrogacy arrangements, in his capacity as a director of Harcourt Limited (a non-NIVF entity). He was granted bail of HKD 10,000 (US$1,285) on November 18, 2025. If convicted, he could face a fine of up to HKD 25,000 (US$3,200) and imprisonment for up to 6 months, which could materially impact the company's business, financial condition, or results of operations due to reputational harm.

Related Party Transactions

• Remuneration paid to directors Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong totaled US$1.76 million in 2025, including a one-time bonus of US$750,000 for maintaining Nasdaq listing status and achieving targeted share capitalization.
• The company paid Harcourt Limited, an entity controlled by Mr. Siu and Ms. Fong, US$230,772 in administrative support fees in 2025.
• Mr. Daniel Siu, son of Mr. Siu, received US$219,045 for consulting services related to fund raising and other capital activities in 2025.
• Mr. Jaspar Siu, son of Mr. Siu, received US$65,000 for consulting services related to fund raising and other capital activities in 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and potential future equity issuances, including convertible notes and equity lines of credit, as well as the dual-class voting structure concentrating control.
• Shareholders are exposed to high operational and financial risks due to the company's rapid and aggressive diversification into speculative ventures (digital assets, real estate, mining) where management has limited experience.
• Employees may benefit from the Share Incentive Plan, which has been expanded to attract and retain talent, but the company's financial instability and operational challenges could impact job security.
• Customers of fertility services may experience changes in service quality or offerings as the company diverts resources to new ventures and faces challenges in its core business.
• Creditors, particularly holders of convertible notes, face risks related to the company's ability to generate sufficient cash flow from operations to service debt, given the widening operating losses.
• Regulatory authorities may increase scrutiny due to the company's diversification into highly regulated and evolving sectors like digital assets and its past non-compliance with SEC filing requirements and Nasdaq listing rules.
• The legal proceedings involving the CEO could lead to reputational damage, impacting investor confidence and potentially affecting business relationships.

Next Steps

• Continue to invest in upgrading laboratories and facilities to maintain technological edge and improve ARS success rates.
• Actively promote technological cooperation with tertiary institutions to improve IVF success rates.
• Develop clinically customized interior design concepts for medical facilities to enhance client experience.
• Maintain and strengthen brand awareness and market share in Asia Pacific through collaborations with local hospitals, companies, and hospitality providers.
• Increase brand awareness through social media promotions and marketing initiatives, and establish a business development team.
• Introduce innovative treatment services, such as IVF mental health services, to attract more clients.
• Expand service reach through strategic acquisitions and/or partnerships in Asia Pacific, focusing on ARS providers with conventional licenses and recognized brands.
• Explore expanding the client base by offering fertility services as part of corporate benefit programs in Asia.
• Establish a home country gynecologist partnership program to offer treatment services with reduced overseas travel requirements.
• Implement measures to address the identified material weakness in internal control over financial reporting, including hiring additional accounting personnel and establishing a financial and system control framework.
• Initiate regular U.S. GAAP and SEC financial reporting training programs for accounting and financial personnel.
• Develop and implement a set of policies and procedures for period-end financial reporting.

Key Dates

Recommendation

The company's core fertility business is in decline, marked by decreasing revenue, gross profit, and a widening operating loss. The reported net income is misleading, being primarily driven by a one-time, non-cash bargain purchase gain. The strategic pivot into highly speculative and unrelated ventures (digital assets, real estate, mining) is fraught with extreme risks, including management's acknowledged lack of experience in these sectors, high market volatility, and significant regulatory uncertainty. Compounding these issues are ongoing Nasdaq compliance challenges, a material weakness in internal controls, and legal proceedings involving the CEO. The substantial potential for dilution from various financing arrangements further exacerbates the risk profile. Given the operational deterioration, high-risk diversification, and governance concerns, the stock presents a very unfavorable investment outlook.

Keywords

Fertility Services, IVF, Digital Assets, Solana, Real Estate Development, SEC Filing, 20-F, Convertible Notes, Bargain Purchase Gain, Nasdaq Listing, Risk Factors, Corporate Governance, Acquisitions, MicroSort, Nodexus, Share Repurchase, Related Party Transactions, Internal Controls, Geopolitical Risk, Thailand, Cambodia, Kyrgyzstan, UAE